JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know

Cerevel Therapeutics Holdings +0.17%

Cerevel Therapeutics Holdings




JP Morgan has decided to maintain its Neutral rating of Cerevel Therapeutics Hldg (NASDAQ:CERE) and raise its price target from $25.00 to $45.00.

Shares of Cerevel Therapeutics Hldg are trading up 0.47% over the last 24 hours, at $42.50 per share.

A move to $45.00 would account for a 5.88% increase from the current share price.

About Cerevel Therapeutics Hldg

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via